Luc Marengère

Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada.

LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada.

Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom.

University Medical Discoveries, Inc. (UMDI) is a venture capital firm located in Toronto.

VisualSonics, Inc. developed vivo imaging systems for non-invasive small animal research. The company was founded by F. Stuart Foster in 1999 and headquartered in Toronto, Canada.

CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA.

Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC.

PRCL Research Inc. is a special purpose company created to develop one compound to proof-of-concept. It engages in the development of a clinical candidate against a novel target for the treatment of chronic inflammatory diseases. The company was founded on October 4, 2013 and is headquartered in Montreal, Canada.

Modulate Therapeutics, Inc. develops a medicine compound designed to re-engage the immune system in order to recognize and eradicate neoplastic disease. The company was founded by September 29, 2015 and is headquartered in Montréal, Canada.

Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden.

AurKa Pharma, Inc. develops medication for cancer treatment. The company was founded by Caroline Fortier and is headquartered in Montreal, Canada.

Acer Therapeutics, Inc. develops therapeutics for the treatment of orphan diseases. Its current pipeline consists of two late-stage clinical products: ACER-002 for vascular Ehlers-Danlos Syndrome (vEDS), and ACER-001 for Maple Syrup Urine Disease (MSUD). The company was founded by Chris Schelling and is headquartered in Cambridge, MA.

Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX.

Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling on March 15, 1991 and is headquartered in Newton, MA.

VG Partners is a private equity investment firm. The private company is based in Toronto, Canada. and has subsidiaries in Canada.

Panthera Dental Inc. engages in prosthetic implant solutions and dental sleep appliances. Its products include metal implant bar, integrated bar, diamart, ReBourke, Copywax, Angulated Screw Channel, and Components and Attachment. The company was founded by Bernard Robichaud, Gabriel Robichaud, and Beatrice Robichaud in 2011 and is headquartered in Quebec, Canada.

Emovi, Inc. offers orthopedic services. It offers services to people suffering from knee osteoarthritis, ligament or meniscus tears, patello-femoral syndrome, tendonitis, and biomechanical deficiencies causing pain and disability. The company was founded in 2002 and is headquartered in Montr?al, Canada.

Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA.